Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Relugolix

FDA-approved product (tablet, oral), marketed as Orgovyx.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Relugolix
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other hormone antagonists and related agents
FDA pharmacologic class
Gonadotropin Releasing Hormone Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Relugolix in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Relugolix with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

    NCT02135445 · start 2014-06

    Registered record
    Registry ID
    NCT02135445
    Conditions
    Prostate Cancer
    Interventions
    TAK-385; Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-06
    Completion
    2015-12
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionTAK-385; Degarelix
    PhasePhase 2
    Registry statusCompleted

  • A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer

    NCT02141659 · start 2014-05-01

    Registered record
    Registry ID
    NCT02141659
    Conditions
    Hormone Treatment-naïve Participants With Prostate Cancer
    Interventions
    TAK-385
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-05-01
    Completion
    2017-04-20
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHormone Treatment-naïve Participants With Prostate Cancer
    InterventionTAK-385
    PhasePhase 1
    Registry statusCompleted

  • A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

    NCT02083185 · start 2014-03-26

    Registered record
    Registry ID
    NCT02083185
    Conditions
    Prostate Cancer
    Interventions
    Relugolix; Leuprorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03-26
    Completion
    2017-02-23
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRelugolix; Leuprorelin
    PhasePhase 2
    Registry statusCompleted

  • A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects

    NCT02093390 · start 2014-03

    Registered record
    Registry ID
    NCT02093390
    Conditions
    Prostate Cancer; Endometriosis
    Interventions
    TAK-385; Fluconazole; Atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-03
    Completion
    2014-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Endometriosis
    InterventionTAK-385; Fluconazole; Atorvastatin
    PhasePhase 1
    Registry statusCompleted

  • A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis

    NCT01452685 · start 2012-03

    Registered record
    Registry ID
    NCT01452685
    Conditions
    Endometriosis
    Interventions
    Placebo; TAK-385; TAK-385; TAK-385; Leuprorelin acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-03
    Completion
    2013-12
    Enrolment
    397

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionPlacebo; TAK-385; TAK-385; TAK-385 +1 more
    PhasePhase 2
    Registry statusCompleted